Cost–effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost–effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer

Published:2024-05-22 Issue:10 Volume:16 Page:669-678
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Liu Ruizhe¹,Zhao Yijia²,Shi Fenghao³⁴,Zhu Jianhong¹,Wu Junyan¹,Huang Min²,Qiu Kaifeng¹

Affiliation:

1. Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou, 510120, China

2. School of Pharmaceutical Sciences, Sun Yat-Sen University, 132 Waihuan East Road, Guangzhou, 511400, Guangdong, China

3. International Research Center for Medicinal Administration, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100871, China

4. School of Pharmaceutical Sciences, Peking University, Beijing, 100871, China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1750743X.2024.2347822

Reference42 articles.

1. Recent advances of immunotherapy for biliary tract cancer

2. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives

3. Biliary tract cancer

4. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data

5. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP